Aspirin use among adults with diabetes: Recent trends and emerging sex disparities

Archives of Internal Medicine

Volumn 164, Issue 22, 2004, Pages 2492-2499

  Persell, Stephen D ^a,b   Baker, David W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; SMOKING; SOCIOECONOMICS;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 10344249915     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.22.2492     Document Type: Article

References (59)

1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998;21: 1138-1145.
2. Haffner SM, Lento S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
3. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-1162.
4. Lotufo PA, Gaziano JM, Chae CU, et al. Diabetes and all-cause coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;161:242-247.
5. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161:1717-1723.
6. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014-1019.
7. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297.
8. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
9. Smith NL, Savage PJ, Heckbert SR, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc. 2002;50:416-423.
10. Meigs JB, Stafford RS. Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. J Gen Intern Med. 2000;15:220-228.
11. Grant RW, Cagliero E, Murphy-Sheeny P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med. 2002;112:603-609.
12. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2751-2753.
13. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
14. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163: 2006-2010.
15. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268:1292-1300.
16. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy: ETORS report number 8. Ophthalmology. 1991; 98(5, suppl):757-765.
17. Hansson L, Zanchetti A, Carruthers SG, et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
18. Rolka DB, Fagot-Campagna A, Venkat Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24:197-201.
19. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 1997;20:1767-1771.
20. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 1997; 20:1772-1773.
21. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Ga: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 1997, 1999, and 2001. Available at: http: //www.cdc.gov/brfss/. Accessed November 6, 2003.
22. Zhang J, Yu KF. What's the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
23. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
24. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241:2035-2038.
25. Merz CN, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol. 2002;40:1877-1881.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
27. National Diabetes Education Program. Be Smart About Your Heart: Control the ABCs of Diabetes. Available at: http://ndep.nih.gov/campaigns/besmart/ besmart_index.htm. Accessed December 22, 2003.
28. New public service campaign depicts serious link between diabetes and heart disease. Available at: http://www.diabetes.org/uedocuments/psa_mtl.pdf. Accessed September 1, 2004.
29. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [published correction appears in BMJ. 1994;308:1540]. BMJ. 1994;308:81-106.
30. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [published correction appears in BMJ. 1994;308:1540]. BMJ. 1994;308:81-106.
31. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26:3264-3272.
32. Tobin JN, Wassertheil-Smoller S, Wexler JP, et al. Sex bias in considering coronary bypass surgery. Ann Intern Med. 1987;107:19-25.
33. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med. 1991;325: 221-225.
34. Krumholz HM, Douglas PS, Lauer MS, Pasternak RC. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med. 1992;116:785-790.
35. Kostis JB, Wilson AC, O'Dowd K, et al: MIDAS Study Group. Sex differences in the management and long-term outcome of acute myocardial infarction: a statewide study: Myocardial Infarction Data Acquisition System. Circulation. 1994; 90:1715-1730.
36. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. Am Heart J. 2000;139:848-857.
37. Nonria A, Vaccarino V, Krumholz HM. Gender differences in mortality after myocardial infarction: why women fare worse than men. Cardiol Clin. 1998;16: 45-57.
38. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-1. Arch Intern Med. 1998;158:981-988.
39. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97:1837-1847.
40. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? the Rancho Bernardo Study [published correction appears in JAMA. 1991;265:3249]. JAMA. 1991;265:627-631.
41. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? the Rancho Bernardo Study [published correction appears in JAMA. 1991;265:3249]. JAMA. 1991;265:627-631.
42. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2002;162:1737-1745.
43. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266: 521-527.
44. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
45. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
46. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
47. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. [published correction appears in Lancet. 2001;357:1134]. Lancet. 2001;357: 89-95.
48. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. [published correction appears in Lancet. 2001;357:1134]. Lancet. 2001;357: 89-95.
49. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wiikins; 1996:845-851.
50. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199-270.
51. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid: the HOT study: Hypertension Optimal Treatment. J Hypertens. 2000; 18:629-642.
52. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002; 136:157-160.
53. Stein AO, Lederman RI, Shea S. The Behavioral Risk Factor Surveillance System questionnaire: its reliability in a statewide sample. Am J Public Health. 1993; 83:1768-1772.
54. Bowlin SJ, Morrill BD, Nafziger AN, et al. Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the Behavioral Risk Factor Survey. J Clin Epidemiol. 1996;49:511-517.
55. Stein AD, Courval JM, Lederman RI, Shea S. Reproducibility of responses to telephone interviews: demographic predictors of discordance in risk factor status. Am J Epidemiol. 1995;141:1097-1106.
56. Bowlin SJ, Morrill BD, Nafziger AN, et al. Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. J Clin Epidemiol. 1993;46:561-571.
57. Centers for Disease Control and Prevention (CDC). Prevalence of diabetes and impaired fasting glucose in adults-United States, 1999-2000. MMWR Morb Mortal Wkly Hep. 2003;52:833-837.
58. O'Connor PJ, Pronk NP, Tan AW, Rush WA, Gray RJ. Does professional advice influence aspirin use to prevent heart disease in an HMO population? Eff Clin Pract. 1998;1:26-32.
59. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care. 2002;25:965-970.